MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-12-31, SNOA had -$474K decrease in cash & cash equivalents over the period. -$811K in free cash flow.

Cash Flow Overview

Change in Cash
-$474K
Free Cash flow
-$811K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-12-31
2025-09-30
2025-06-30
Net loss
-819 -534 -1,241
Depreciation
34 36 36
Stock-based compensation
24 39 57
Deferred tax asset
--141 -
Deferred income taxes
-107 --93
Operating lease right-of-use asset
161 -56 448
Accounts receivable, net
-340 78 216
Inventories, net
40 -208 652
Prepaid expenses and other current assets
392 15 819
Deferred consideration, net of discount
62 59 55
Accounts payable
229 -666 1,026
Accrued expenses and other current liabilities
78 158 -484
Withholding tax payable
109 110 104
Operating lease liabilities
162 -56 448
Deferred revenue
-449 0 26
Net cash (used in) provided by operating activities
-764 -635 -2,015
Purchases of property and equipment
47 10 106
Net cash used in investing activities
-47 -10 -106
Proceeds from issuance of common stock, net of offering expenses
266 0 0
Proceeds from exercise of employee stock options
0 21 23
Payments for fractional shares related to reverse-split
0 0 -
Principal payments on short-term debt
56 83 81
Net cash provided by financing activities
210 -62 -58
Effect of exchange rate on cash and cash equivalents
127 137 410
Net (decrease) increase in cash and cash equivalents
-474 -570 -1,769
Cash and cash equivalents at beginning of period
3,035 5,374 -
Cash and cash equivalents at end of period
2,561 3,035 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Sonoma Pharmaceuticals, Inc. (SNOA)

Sonoma Pharmaceuticals, Inc. (SNOA)